Onsdag 28 Oktober | 21:00:29 Europe / Stockholm

All ägardata du vill ha finns i Holdings!

Herantis H2 2023 - Presented positive phase I data

2024-03-11 16:04:00

Redeye reviews the case of Herantis in the wake of progress with clinical candidate HER-096 and H2 report last week. We reiterate our positive view of the company.

Read more and download the Research Update.
 
Follow companies at Redeye to receive the latest equity research within Life Science and Technology.
 
This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/